Sacituzumab govitEcan in THYroid Cancers

SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC). The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.

Trial Details

NCT ID
NCT06235216
Phase
PHASE2
Sponsor
Grupo Espanol de Tumores Neuroendocrinos
Status
RECRUITING
Cancer Type
Anaplastic Thyroid Cancer
Interventions
  • Sacituzumab govitecan
Locations (sample)
  • Barcelona, Spain|41.38879,2.15899
  • Ferrol, Spain|43.48451,-8.23293
  • Hospitalet de Llobregat (Barcelona), Spain|41.35967,2.10028
  • Madrid, Spain|40.4165,-3.70256
  • Madrid, Spain|40.4165,-3.70256

Key Eligibility Criteria

  • Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent.
  • Patient is ≥ 18 years of age.
  • Patient has histologically confirmed metastatic or locally advanced unresectable radioactive-iodine refractory differentiated thyroid cancer (cohor…
  • Prior therapy in each cohort:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Anaplastic Thyroid Cancer Trials on Trialify →